The “self” in pain: high levels of schema-enmeshment worsen fibromyalgia impact

Myrella Paschali1*, Asimina Lazaridou1, Eric S. Vilsmark1, Jeungchan Lee2, Michael Berry2, Arvina Grahl2, Alessandra Anzolin2, Marco Loggia2, Vitaly Napadow1,2 and Robert R. Edwards1

Abstract

Objective: Chronic pain can have detrimental effects on quality of life and a profound impact on one’s identity. The Pictorial Representation of Illness- and Self-Measure (PRISM), is a visual tool designed to measure the self-illness separation (SIS) that represents the degree of schema-enmeshment (i.e., the degree to which the self-schema and the illness-schema come to overlap). Our aim was to investigate the relationship between schema-enmeshment and pain-related outcomes in patients with fibromyalgia.

Methods: In this cross-sectional study, 114 patients with fibromyalgia completed self-report assessments of pain catastrophizing, pain severity and interference, impact of symptoms, anxiety, and depression. SIS was assessed using an iPad version of PRISM. Mediation analyses evaluated the mediating role of schema-enmeshment on the association between pain catastrophizing and fibromyalgia impact.

Results: A higher degree of schema-enmeshment was associated with greater pain catastrophizing, pain severity and interference, impact of symptoms, and depression. Moreover, a mediation analysis revealed that schema-enmeshment significantly mediated the association between pain catastrophizing and fibromyalgia impact (p < 0.001).

Conclusions: Our results indicate that schema-enmeshment is associated with greater intrusiveness of chronic pain on everyday life, thereby posing significant limitations on the emotional and physical well-being of fibromyalgia patients. Schema-enmeshment also appears to partly account for the deleterious effect of pain catastrophizing on disease impact. The PRISM is a simple tool that may uniquely capture the extent to which chronic pain and illness infiltrates and affects one’s self-concept.

Keywords: Chronic pain, Enmeshment, Fibromyalgia, Self, Schema-enmeshment, PRISM, Self-illness-separation

Introduction

Chronic pain can substantially interfere with quality of life and daily functioning [1, 2] and is strongly associated with depression, anxiety, fatigue, and suffering [3–6]. Due to its enormous negative impact on one’s life, chronic pain can adversely affect a person’s identity or self-schema [7]. This might manifest as a loss of the sense of self and diminution of the defining aspects of a life (e.g., reductions in the sense of oneself as an accomplished, productive, socially engaged human being) as a result of living with chronic pain. The experienced loss of identity, meaning and autonomy are often considered to be a core component of suffering, especially the suffering associated with chronic pain [8, 9]. The Schema Enmeshment Model of Pain was developed in 2001 by Pincus and Morley to characterize and further elucidate changes in self resulting from chronic pain. This model consists of multiple schemas: self, illness, and pain-related schemas.
that can become enmeshed if their elements overlap significantly. The degree of schema-enmeshment (i.e., the degree to which the self-schema and the illness-schema come to overlap, such that the one’s identity is defined by illness) is thought to partly determine the emotional adjustment to chronic pain [9].

Although pain is nearly ubiquitous, the individual pain experience and suffering are multifaceted and related to numerous psychosocial constructs and processes [10]. Determining how to measure the impact of chronic pain on the self can be challenging, as the notion of “self” is an abstract, subjective experience. Measurements which incorporate patient perspectives on the self can offer insight into these intangible factors that otherwise evade traditional approaches of objective pain measurement. To date, typical methods for assessing the impact of chronic pain on the self have relied on lengthy questionnaires that require adequate language competency to complete. In contrast, the Pictorial Representation of Illness and Self-Measure (PRISM) encapsulates a single multifactorial measurement with simple instructions in a short amount of time. The PRISM is a simple test created by Büchi and colleagues [11] to measure what in German is Leidensdruck, the burden of suffering due to illness. Burden of suffering is defined as “a state of severe distress associated with events that threaten the intactness of the person” [12]. This term not only encompasses physical aspects of illness, but also the illness’s psychological effects and the extent to which it impedes a patient’s daily life and relationships. The PRISM measures the self-illness-separation (SIS) [8, 11] which quantifies the schema-enmeshment between self and illness and is equivalent to the degree to which the illness defines, intrudes upon, or threatens the sense of self [9, 13].

To complete the PRISM, participants are instructed to arrange two discs on a flat surface, labeled “self” and “illness”, according to their own experience with illness. The task can be conducted through a number of media including patients using a pencil and paper [14] or digital tools such as a mouse to move the illness circle on screen [13] or a touch screen [15]. The validity of the PRISM has been demonstrated numerous times for an array of chronic disorders including dizziness [14], psoriasis [16], tinnitus [15], and chronic pain [17]. The proximity of the discs quantifies the SIS score; the closer the 2 discs are to overlapping, the greater the enmeshment of self with concepts of illness. The SIS scores for these patient populations generally correlate negatively with measures of severity of illness, depression, and other adverse health-related quality of life impacts that are measured by typical patient-reported outcomes, i.e., a shorter distance between the discs is associated with greater illness severity, psychosocial impact of illness, etc.

The current literature shows increasing attention to the relationship on the self and pain [18]. The measure of illness identity that is most used in pain is the Illness Perception Questionnaire (IPQ) that includes the subscale “identity” [19]. The IPQ correlates moderately with catastrophizing; however, it doesn’t correlate with the SIS measured by the PRISM [13]. Further, Sun et al. found that illness identity and perceptions (measured using the IPQ) do not fully explain the effects of catastrophizing on pain [20]. These previous reports indicate that the PRISM assesses a distinct construct compared to the IPQ and highlight the importance of studying the SIS in relation to catastrophizing. Additionally, to our knowledge, no other study has utilized PRISM to investigate the relationship between the self and pain in fibromyalgia patients. Thus, the present study seeks to expand the existing literature by investigating the relationships between schema-enmeshment and pain-related outcomes such as pain catastrophizing in this patient population. Fibromyalgia is a complex chronic pain condition characterized by widespread pain, fatigue, disturbed sleep, anxiety, depression, cognitive problems and impaired functioning [21]. Prior work has suggested that patients with fibromyalgia demonstrate significant schema-enmeshment when compared to a control group [22]. The PRISM task has been validated for measuring the SIS in a mixed population of chronic pain sufferers [17], but it has only rarely been studied as a contributor to adverse chronic pain-related outcomes. We hypothesized that the distance between self and illness discs (i.e., the SIS) would be negatively correlated with fibromyalgia pain severity, pain-related catastrophizing, and other measures of distress. Furthermore, we hypothesized that schema-enmeshment would mediate the established associations of cognitive and affective factors (e.g., pain catastrophizing) with the severity and impact of chronic fibromyalgia pain, as prior studies have suggested that the degree of schema-enmeshment could determine emotional adjustment to chronic pain [9].

Methods
This baseline data collection was part of a larger neuroimaging clinical study performed at the A. A. Martinos Center for Biomedical Imaging in Boston, Massachusetts. Patients diagnosed with fibromyalgia according to American College of Rheumatology criteria, which require the presence of widespread pain as well as several somatic and cognitive symptoms [23] were screened (n = 216). The inclusion criteria used to screen potential participants were: (1) 18–75 years old, (2) female, (3) Wolfe et al.’s [21] research criteria for fibromyalgia diagnosis for at least 1 year, (4) at least 4 out of 10 average baseline pain intensity, and pain reported for at least 50% of days, (5)
fluent in English, and able to provide written informed consent. The exclusion criteria were: (1) comorbid acute pain conditions or comorbid chronic pain conditions rated by the subject as more painful than fibromyalgia, (2) current use of stimulants (e.g. modafinil), (3) pregnant or nursing women, (4) psychiatric disorder with a history of psychosis (e.g. schizophrenia), (5) recent psychiatric hospitalization (past 6 months), (6) current or recent use of recreational drugs, (7) active suicidal ideation, (8) autoimmune or inflammatory disease (RA, SLE, IBD) that causes pain, (9) documented peripheral neuropathy of known cause, and (10) lower limb vascular surgery or current lower limb vascular dysfunction.

**Sociodemographic data**
The collected sociodemographic information included age, marital status, race, current occupational status, and educational level.

**Clinical measures**

**Pain Catastrophizing**
The Pain Catastrophizing Scale (PCS) is a 13-item, widely used, self-report measure of catastrophic thinking associated with pain. The PCS consists of three subscales: rumination, magnification, and helplessness. The PCS is well-validated in chronic pain and has shown good psychometric properties in pain patients and controls [24].

**Pain severity and interference**
To measure pain, we used the Brief Pain Inventory (BPI), a 15-item measure, that consists of two multi-item subscales that measure pain intensity and pain interference with daily activities. The BPI is well-validated in chronic pain populations and is frequently recommended as an outcome measure of pain severity and pain interference [25].

**Fibromyalgia impact**
The Fibromyalgia Impact Questionnaire-Revised (FIQR) is 21-question measure with an 11-point numeric rating scale (NRS) of 0 to 10, with 10 being “worst”. The questionnaire is divided into three domains assessing: (a) Function, (b) Overall impact, and (c) Fibromyalgia symptoms. All FIQR items reference a time frame of the past 7 days. The FIQR has sound psychometric properties [26].

**Emotional distress**
**Anxiety and Depression.** Participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression short forms, which have been repeatedly validated in chronic pain populations [27, 28] including fibromyalgia [29]. The anxiety subscale consists of 7 items and measures the frequency with which emotions such as fear, stress, and anxiety are experienced by the patient on a scale from “never” to “always”. The depression subscale consists of 8 items that similarly measure the frequency with which emotions such as worthlessness, hopelessness, and sadness are experienced. Higher scores signify higher levels of emotional distress.

**PRISM task**
We used an electronic version of the PRISM task on an iPad, which has been used in previous studies to assess the SIS [15, 30]. In order to permit a comparison with previous studies conducted using a white letter-sized metal board (DIN-A4) with a fixed, yellow circle (diameter 70 mm) glued in the bottom left-hand corner, all formats were normalized from the display of the iPad (147 × 196 mm) to DIN-A4 format (210 × 297 mm). The following descriptions are based on the DIN-A4 format. Participants were presented with a white panel taking up the whole display of the iPAD, with a yellow “self” disc affixed to it at the bottom right-hand corner (diameter 70 mm) and a movable red “fibromyalgia” disc (diameter 50 mm) in the middle of the screen. Patients were asked to imagine that the white surface is their life at the present moment, the yellow fixed disc represents themselves and the colored red disc reflects their fibromyalgia illness. Patients were then instructed to place the red disc representing fibromyalgia, in relation to the fixed disc representing their self (Fig. 1). The PRISM was scored by measuring the distance from the center of the yellow “self” disc to the center of the red “fibromyalgia” disc. The distance in millimeters between the two discs is defined as the SIS (SIS range 0–256 mm) [11].

**Procedures**
The data, including informed consent, completion of the above-mentioned questionnaires, and the PRISM task, was collected during a baseline visit of a larger neuroimaging study.

**Statistical analysis**
Demographic and clinical characteristics were assessed and reported as means and standard deviations (SD) for continuous variables and percentages for dichotomous variables. Similar to two previous studies in orofacial pain and tinnitus patients [15, 31], SIS was divided into two groups reflecting the degree of schema-enmeshment. In the low-SIS group, the red “fibromyalgia” disc was overlapping with or was completely placed inside the yellow self-circle, i.e., patients were placed in this group if they reported a SIS smaller than 60 mm (overlap is represented by smaller values than the sum of
both circle radii: self 35 mm + illness 25 mm). In the high-SIS group the red “fibromyalgia” disc was placed outside the yellow “self” disc (SIS ≥ 60 mm). Possible differences between participants with low and high SIS scores were assessed utilizing a Mann-Whitney test for independent samples separately on each clinical measure and a chi-square test for sociodemographic measures. In addition, we calculated Pearson correlations to explore associations between all variables. We then performed hierarchical linear regression analyses predicting fibromyalgia impact (FIQR). Finally, we performed mediation analysis (PROCESS, model 4) to examine whether the SIS mediated the relationship between pain catastrophizing (PCS) and fibromyalgia impact (FIQR). A custom written macro (PROCESS; www.processmacror.org) for SPSS (v26, IBM, USA) was used to perform multiple mediation pathway analysis with bias-corrected bootstrapping tests. Bootstrapping is a statistical method that involves drawing repeated samples from the data with replacement to gain multiple estimates (5000 bootstrap samples) of the indirect effect attributed to potential mediator variables [32, 33]. Bootstrapping provides a way of circumventing power deficiencies of normal theory tests (i.e. Sobel) typically introduced by the non-normality in the sampling distribution [34, 35]. Bias-corrected 95% confidence intervals were produced for each potential mediator and were used to test the significance of the total and indirect (i.e. mediation) effects. Estimates of indirect effects were considered significant in the case that zero was not included within the confidence intervals [36].

Results
Subject characteristics
One-hundred-and-fourteen (N = 114) participants with fibromyalgia were eligible for participation. Within this group, 92 provided complete data regarding the PRISM task. The average age of patients was 41.2 ± 12.4 years. The mean SIS was 62 mm and the median was 36 mm, indicating that the majority of participants placed the “fibromyalgia” disc in such a way that the “self” and “fibromyalgia” discs were overlapping. Further
sociodemographic and clinical characteristics are reported in Table 1.

**Associations between the SIS and demographic and clinical characteristics**

No significant results were found correlating the SIS score with age, employment, marital status, level of education and income. SIS was negatively correlated with pain catastrophizing, pain severity and interference, fibromyalgia impact, and depression. SIS did not correlate with anxiety (Table 2).

**Clinical characteristics of participants with low and high SIS**

The means of the clinical characteristics for each PRISM group and the results of their statistical comparison (Mann-Whitney test) can be found in Table 3. Patients reporting a higher degree of schema-enmeshment (low SIS group; mean SIS 20 mm) had higher scores for catastrophizing, pain severity and interference, fibromyalgia impact, anxiety, and depression compared to patients with lower schema-enmeshment (high SIS group; mean SIS 14.4 mm). There were no significant differences in the sociodemographic characteristics of the low and high SIS groups.

**SIS as a predictor of disease impact**

Results of a linear regression predicting the level of fibromyalgia impact (FIQR) showed that catastrophizing and the SIS collectively explained 32% of the variance in FIQR ($F(2,87) = 20.88$, $p < 0.001$, $r^2 = .324$). The individual predictors were examined further and indicated that catastrophizing ($p < 0.001$) and the SIS ($p < 0.05$) were significant predictors for level of fibromyalgia impact (FIQR) in the model (Table 4).

### Table 2 Correlations with Self-Illness-Separation (SIS)

|      | SIS          | PCS  | BPI Sev. | BPI Interf. | FIQR  | Anxiety | Depression |
|------|--------------|------|----------|-------------|-------|---------|------------|
| SIS  | –             | –.37 | –.28     | –.24        | –.37  | –.09    | –.28       |
| PCS  | –.37         | –    | –.50     | –.59        | .59   | .52     | .58        |
| BPI Severity | –.28      | .50  | –        | .73         | .67   | .22     | .31        |
| BPI Interference | –.24    | .59  | .73      | –           | .78   | .37     | .51        |
| FIQR | –.37         | .59  | .67      | .77         | –     | .42     | .53        |
| Anxiety (PROMIS) | –.09     | .52  | .22      | .37         | .42   | –       | .60        |
| Depression (PROMIS) | –.28      | .58  | .31      | .51         | .53   | –       | –          |

*Note.* Correlation is significant at the 0.05 level (two-tailed); **Correlation is significant at the 0.01 level (two-tailed); PCS Pain Catastrophizing; BPI Brief Pain Inventory; FIQR Fibromyalgia Impact Questionnaire-Revised; PROMIS Patient-Reported Outcomes Measurement Information System (T-Score)*

### Table 3 Clinical and sociodemographic characteristics of participants with low and high SIS (mean ± SD)

|                    | Low SIS (high enmeshment) (n = 61) | High SIS (low enmeshment) (n = 31) | p-value |
|--------------------|----------------------------------|-----------------------------------|---------|
| Age                | 42.7 ± 12.33                     | 38.65 ± 11.64                     | .203    |
| Caucasian (n)      | 47                               | 24                                | .326    |
| Employed (n)       | 29                               | 19                                | .212    |
| Married (n)        | 20                               | 11                                | .796    |
| Living alone (n)   | 11                               | 3                                 | .292    |
| Education Level (college degree) (n) | 38                        | 21                                | .607    |
| Annual Income (above $45000) (n) | 35                        | 22                                | .204    |
| PCS                | 25.66 ± 11.60                    | 17.61 ± 10.78                     | .002    |
| BPI Severity       | 5.59 ± 1.62                      | 4.27 ± 1.92                       | .001    |
| BPI Interference   | 6.28 ± 2.11                      | 4.56 ± 2.41                       | .001    |
| FIQR               | 62.00 ± 13.39                    | 46.36 ± 16.76                     | .000    |
| Anxiety (PROMIS)   | 60.27 ± 7.74                     | 56.40 ± 9.20                      | .045    |
| Depression (PROMIS)| 59.79 ± 8.83                     | 53.81 ± 8.54                      | .002    |

*Note.* SIS Self-Illness-Separation; PCS Pain Catastrophizing; BPI Brief Pain Inventory; FIQR Fibromyalgia Impact Questionnaire-Revised; PROMIS Patient-Reported Outcomes Measurement Information System (T-Score).
SIS as a mediator of the relationship between catastrophizing and fibromyalgia impact

Figure 2 depicts the results of the mediation analysis. The results indicate that SIS mediated the influence of pain catastrophizing on fibromyalgia impact. All paths within the model were significant: pain catastrophizing was negatively associated with SIS (path \( a = -0.37, p < .001 \)) and positively associated with fibromyalgia impact (path \( c = 0.64, p < .001 \)). SIS was significantly negatively associated with fibromyalgia impact (path \( b = -0.19, p < .001 \)).

Discussion

The present study aimed to assess the interplay of psychosocial factors with patients’ perceived degree of schema-enmeshment measured using the PRISM task in patients with fibromyalgia. Our results support the hypothesized relationship between schema-enmeshment with pain catastrophizing, clinical pain severity, fibromyalgia impact, and depression. The closer the patients placed the ‘illness’ disc relative to the ‘self’ disc (greater schema-enmeshment), the more intense daily fibromyalgia pain they experienced and the more catastrophizing, depression, and fibromyalgia impact on their lives they reported. These findings are broadly consistent with previous validation studies of the PRISM [8, 17]. Our results also indicated that greater schema-enmeshment was associated with greater intrusiveness of the illness into patients’ everyday life. Our results also suggested that the more schema-enmeshment patients are reporting the more significant the fibromyalgia-related limitations are in their emotional and physical well-being. A similar pattern of results was obtained in a different population with a chronic illness [16]. An important observation was that sociodemographic variables did not correlate with the degree of schema-enmeshment, which suggests that our results may be applicable to participants of different age and socioeconomic groups. It is interesting to note that the average SIS of fibromyalgia patients in our study (mean = 62 mm) was substantially lower compared to other chronic diseases such as tinnitus (mean = 93 mm; iPad version, results normalized to a DIN-A4 format.) [15], or lupus erythematosus (mean = 140 mm; paper version - DIN-A4 format) [37]. While the present study does not include a chronic pain comparison group, it is possible that the complex and disabling nature of fibromyalgia is characterized by greater schema-enmeshment and suffering than other chronic diseases in which the PRISM has been used.

Both pain catastrophizing and schema-enmeshment were found to be significant predictors for fibromyalgia

Table 4 Linear Regression Analyses Results for Variables Predicting Fibromyalgia Impact (FIQR)

| Variable                        | B   | SE | \( \beta \) |
|---------------------------------|-----|----|------------|
| Pain Catastrophizing (PCS)      | .64 | .13| .47***     |
| Self-Illness-Separation (SIS)   | -.58| .28| -.19*      |

Note: \( R^2 = .32, F = 20.88***; \) * \( p < .05 \), ** \( p < .01 \), *** \( p < .001 \)
impact, suggesting that fibromyalgia patients high in catastrophizing and schema-enmeshment are more likely to experience a higher fibromyalgia impact. This aligns with previous findings [38] on the association of pain catastrophizing and illness identity. Prior reviews have noted that pain catastrophizing is common in individuals with fibromyalgia [39] and has been shown to be the most consistent psychosocial factor predicting adjustment to chronic pain and contributing to a delayed recovery from chronic musculoskeletal pain [40]. Results of a previous study showed that patients with fibromyalgia who endorsed greater levels of catastrophizing perceived their disease impact to be higher compared to patients with lower catastrophizing scores [41]. We therefore examined the role schema-enmeshment plays in the relationship between pain catastrophizing and fibromyalgia impact. Our mediation analysis results indicate that the degree of schema-enmeshment serves as a mediator between catastrophizing and fibromyalgia impact, indicating that increased schema-enmeshment acts as one potential pathway by which catastrophizing exerts a deleterious effect on disease impact.

Broadly, the present findings highlight the importance of illness beliefs in shaping pain-related outcomes in fibromyalgia and illuminate the potential benefits of incorporating measures of identity and self-concept, such as the PRISM, in biopsychosocial studies of chronic pain. Taken together, our results indicate that schema-enmeshment might be one of the pathways implicated in the maintenance of interfering fibromyalgia symptoms in the patient’s life. Such results may have important clinical implications for clinicians involved in the treatment of patients with fibromyalgia. The use of PRISM in clinical settings can efficiently help to identify patients with a greater burden of suffering and with greater identity vulnerability. The acquired information could then be utilized in the determination of the most suitable treatment option for the patient. For example, a patient with high schema-enmeshment could be a good candidate for Acceptance and Commitment Therapy (ACT), since schema-enmeshment is related to one's adjustment to or acceptance of their chronic illness [42]. Additional benefits of using the PRISM in clinical settings are its simple and fast administration and the facilitation of an in-depth discussion about the impact of fibromyalgia has on the patient’s identity during, for example, a psychotherapeutic session.

Our study has some limitations which are worth noting. Firstly, the pain-related outcomes were measured only using self-report measures, which can be subject to a variety of biases. Secondly, although this study has identified associations between schema-enmeshment and pain-related variables, its cross-sectional nature does not allow conclusions as to cause and effect. That is, whether high levels of pain catastrophizing, depression and disease severity cause elevations in enmeshment over time, or whether the enmeshment of self and illness contributes causally to pain impact, catastrophizing, and other adverse outcomes is unclear. Longitudinal studies will be necessary to definitively answer these questions. It is known that psychosocial factors can interact with pain experiences in a non-linear and complex way; psychosocial characteristics can serve as vulnerability factors [43] or develop for the first time as a response to the ongoing pain experience [44]. We suggest that the relationship between schema-enmeshment and the investigated pain-related variables is likely to be bi-directional, but prospective research is needed to shed light on the temporal dynamics of these relationships. Lastly, our study did not utilize a conventional measure for illness identity such as the IPQ.

Conclusions
The present study uses a novel diagnostic instrument, a fairly large clinical sample, and formal mediation analysis to explore the role of schema-enmeshment among patients with fibromyalgia. Our results illustrate that the PRISM can serve as a unique tool capturing the extent to which chronic pain and illness infiltrates and affects one’s self-concept. Taking into consideration that PRISM is easy and fast to administer, we recommend that PRISM might serve as an additional valuable diagnostic tool in clinical contexts assessing the burden of suffering and schema-enmeshment in patients with fibromyalgia. Although not investigated in the present study, we expect that a reduction of schema-enmeshment could potentially lead to improvement of pain-related outcomes. We propose that nonpharmacologic, psychosocially-oriented treatments such as cognitive behavioral therapy and ACT (which have demonstrated efficacy in FM [45, 46]) may be suitable interventions in this regard. The effectiveness of interventions aiming to reduce the degree of schema-enmeshment, and the mechanisms by which those interventions affect pain-related outcomes, should be explored in future studies.

Abbreviations
PRISM: Pictorial Representation of Illness- and Self-Measure; SIS: Self-Illness Separation; PCS: Pain Catastrophizing Scale; BPI: Brief Pain Inventory; FIQR: Fibromyalgia Impact Questionnaire-Revised; PROMIS: Patient-Reported Outcomes Measurement Information System; SD: Standard Deviation; ACT: Acceptance and Commitment Therapy.

Acknowledgements
Not applicable.
Authors’ contributions
All authors contributed equally to this work. The author(s) read and approved the final manuscript.

Funding
This research was supported by NIH grant R01-AR064367–05, R33-AR064367–05, P01-AT009965–02 by grants to RRE and VN from The National Institute of Arthritis and Musculoskeletal and Skin Disease. This funding source had no role in the design of this study and its execution, analyses, interpretation of the data, or decision to submit results.

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Study procedures received approval by the Institutional Review Board (IRB) of Brigham & Women’s Hospital (Boston, MA, USA; protocol number 2009P001021). All participants provided written informed consent and all procedures were conducted according to the Declaration of Helsinki.

Consent for publication
N/A

Competing interests
The authors declare no conflict of interest.

Author details
1 Department of Anesthesiology, Harvard Medical School, Brigham & Women’s Hospital, 850 Boylston St, Suite 302, Chestnut Hill, MA 02467, USA. 2 Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.

Received: 20 April 2021 Accepted: 22 September 2021 Published online: 12 October 2021

References
1. Treede RD, Rief W, Barke A, Aziz Q, Bennett MJ, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain. 2019;160(1):19–27.
2. Institute of Medicine Committee on Advancing Pain Research C. Education: The National Academies Collection: Reports funded by National Institutes of Health. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press (US) National Academy of Sciences; 2011.
3. Sheng J, Liu S, Wang Y, Cui R, Zhang X. The link between depression and chronic pain: neural mechanisms in the brain. Neuroplast. 2012;2012:9724371.
4. Freidin MB, Wells H, Potter T, Livshits G, Menni C, Williams FMK. Metabolomic markers of fatigue: association between circulating metabolite and fatigue in women with chronic widespread pain. Biochim Biophys Acta Mol basis Dis. 2018;1864(2):601–6.
5. Gómez Penedo JM, Rubel JA, Blättler L, Schmidt SJ, Stewart J, Egloff N, Grosse Holtforth M. The complex interplay of pain, depression, and anxiety symptoms in patients with chronic pain: a network approach. Clin J Pain. 2020;36(4):249–59.
6. Schulz R, Monin JK, Czaja SJ, Lingler JH, Beach SR, Martire LM, et al. Measuring the experience and perception of suffering. The Gerontologist. 2010;50(6):774–84.
7. Harris S, Morley S, Barton SB. Role loss and emotional adjustment in chronic pain. Pain. 2003;105(1–2):363–70.
8. Büchi S, Buddeberg C, Klugehofer R, Russi EW, Brändli O, Schlässer C, et al. Preliminary validation of PRISM (pictorial representation of illness and self measure) - a brief method to assess suffering. Psychother Psychosom. 2002;71(6):333–41.
9. Pincus T, Morley S. Cognitive-processing bias in chronic pain: a review and integration. Psychol Bull. 2001;127(5):599–617.
10. Edwards RR, Dworin RH, Sullivan MD, Turk DC, Watan AD. The role of psychosocial processes in the development and maintenance of chronic pain. J Pain. 2016;17(9 Suppl):T70–92.
11. Büchi S, Sensky T, Sharpe L, Timberlake N. Graphic representation of illness: a novel method of measuring patients’ perceptions of the impact of illness. Psychother Psychosom. 1998;67(4–5):222–5.
12. Cassel EJ. The nature of suffering and the goals of medicine. N Engl J Med. 1982;306(11):639–45.
13. Denton F, Sharpe L, Schröier L. PRISM: enummehng of illness and self-schema. Psychother Psychosom. 2004;73(1):57–63.
14. Weidt S, Bruehl AB, Moergeli H, Straumann D, Hegemann S, Büchi S, et al. Genetic representation of the burden of suffering in dizziness patients. Health Qual Life Outcomes. 2014;12:184.
15. Peter N, Kleijnjng T, Horat L, Schmidt-Weitmann S, Meyer M, Büchi S, et al. Validation of PRISM (pictorial representation of illness and self measure) as a novel visual assessment tool for the burden of suffering in inpatient patients. Health Qual Life Outcomes. 2016;14:47.
16. Fotiou K, Hofmann M, Kaufmann R, Thaci D. Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of priorsiass. J Eur Acad Dermatol Venereol. 2015;39(12):2356–62.
17. Kassardjian CD, Gardner-Nix J, Dupak K, Barbati J, Lam-McCullock J. Validating PRISM (pictorial representation of illness and self measure) as a measure of suffering in chronic non-cancer pain patients. J Pain. 2009;9(12):1135–43.
18. Morley S. The self in pain. Rev Pain. 2010;4(1):24–7.
19. Weimann J, Petrie KJ, Moss-morris R, Horne R. The illusion perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health. 1996;11(3):431–45.
20. Sun PQ, Walbeehm ET, Sellers RW, Jansen MC, Slipper HP, Ulrich DIO, et al. Influence of illness perceptions, psychological distress and pain catastrophizing on self-reported symptom severity and functional status in patients with carpal tunnel syndrome. J Psychosom Res. 2019;126:19820.
21. Wolf F, Claau D, Fitzcharles MA, Goldberg DL, Hauser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38(6):1113–22.
22. Compañ V, Feixas G, Varlotta-Dominguez N, Torres-Viñals M, Aguilar-Alonso Á, Dada G, et al. Cognitive factors in fibromyalgia: the role of self-concept and identity related conflicts. J Constro Psychol. 2011;24(1):56–77.
23. Wolfe F, Claau D, Fitzcharles MA, Goldberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity: Arthritis Care Res (Hoboken). 2010;62(5):600–10.
24. Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O’Neill E. Factor structure, reliability, and validity of the pain Catastrophizing scale. J Behav Res (Hoboken). 2010;62(5):600–10.
25. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23(2):129–38.
26. Bennett RM, Friend RCS, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQ(R)): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120.
27. Pilkonis PA, Choi SW, Salaman JM, Butt Z, Moore TL, Lawrence SM, et al. Assessment of self-reported negative affect in the NIH textbook. Psychiatry Res. 2013;206(1):89–97.
28. Cella D, Riley W, Kopp BA, Hauptmann W, Jones J, O’Neill E. Factor structure, reliability, and validity of the pain Catastrophizing scale. J Behav Res (Hoboken). 2010;62(5):600–10.
29. Celli D, Riley W, Stone A, Rothrock N, Reeve B, Moore TL, Lawrence SM, et al. Assessment of self-reported negative affect in the NIH textbook. Psychiatry Res. 2013;206(1):89–97.
30. Kabar I, Hüsingu-Kabar A, Maschmeier M, Völler C, Dümke M, Schmidt HH, et al. Preliminary validation of PRISM (pictorial representation of illness and self measure) as a novel visual assessment tool for the burden of suffering in transplant recipients. Ann Transplant. 2018;23:674–80.
31. Streffer ML, Buchi S, Motegi H, Galli U, Ettlin D. PRISM (pictorial representation of illness and self measure): a novel visual instrument to assess pain and suffering in orofacial pain patients. J Orofac Pain. 2009;23(2):140–6.
32. Hayes A. Introduction to mediation, moderation and conditional Process analysis. New York: Guilford Press; 2013.
33. Cheung GW, Lau RS. Testing mediation and suppression effects of latent variables: bootstrapping with structural equation models. Organ Res Methods. 2008;11(2):296–325.
34. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83–104.
35. Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol Methods. 2002;7(4):422–45.
36. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879–91.
37. Buchi S, Villiger P, Kauer Y, Klaghofer R, Sensky T, Stoll T. PRISM (pictorial representation of illness and self measure)- a novel visual method to assess the global burden of illness in patients with systemic lupus erythematosus. Lupus. 2000;9(5):368–73.
38. Chisari C, Chilcot J. The experience of pain severity and pain interference in vulvodynia patients: the role of cognitive-behavioural factors, psychological distress and fatigue. J Psychosom Res. 2017;93:83–9.
39. Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol. 2011;7(4):216–24.
40. Martinez-Calderon J, Jensen MP, Morales-Asencio JM, Luque-Suarez A. Pain Catastrophizing and function in individuals with chronic musculoskeletal pain: a systematic review and Meta-analysis. Clin J Pain. 2019;35(3):279–93.
41. Angarita-Osorio N, Pérez-Aranda A, Feliu-Soler A, Andrés-Rodríguez L, Borras X, Suso-Ribera C, et al. Patients with fibromyalgia reporting severe pain but low impact of the syndrome: clinical and pain-related cognitive features. Pain Pract. 2020;20(3):255–61.
42. Sutherland R, Morley S. Self-pain enmeshment: future possible selves, sociotropy, autonomy and adjustment to chronic pain. Pain. 2008;137(2):366–77.
43. Afari N, Ahumada SM, Wright LJ, Mostoufi S, Golsari G, Reis V, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med. 2014;76(1):2–11.
44. Crombez G, Eccleston C, Van Damme S, Vlaeyen JW, Karoly P. Fear-avoidance model of chronic pain: the next generation. Clin J Pain. 2012;28(6):475–83.
45. Karlsson B, Burell G, Anderberg UM, Svärdsson K. Cognitive behaviour therapy in women with fibromyalgia: a randomized clinical trial. Scand J Pain. 2015;9(1):11–21.
46. Simister HD, Tkachuk GA, Shay BL, Vincent N, Pear JJ, Skrabek RQ. Randomized controlled trial of online acceptance and commitment therapy for fibromyalgia. J Pain. 2018;19(7):741–53.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.